# US 2025/0368682 A1 · Novel polypeptide composition for intracellular transfection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368682 A1
- Document ID: US20250368682A1
- Status: Published application
- Kind: A1
- Application number: 19/108,151
- Filed: 2023-09-07
- Published: 2025-12-04
- Earliest claimed: 2022-09-08
- Assignees: Azothbio Inc.
- Applicants: Azothbio Inc.
- Inventors: Jae Min Shin; Jung-Hyun Park; Ji Yeon Chang; Song Mi Kim; Meriem Bouchane
- Web page: https://patentgrep.com/patent/US20250368682A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/09: containing a nuclear localisation signal
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure pertains to: a novel polypeptide composition for intracellular transfection; and uses thereof. This novel polypeptide composition for intracellular transfection has the advantage of greatly improving the transfection efficacy of target substances and having remarkably low cytotoxicity. Accordingly, the polypeptide composition has a variety of uses since various substances can be transported into cells thereby.

## Claims

### Claim 1

A polypeptide comprising: 9, 10, or 11 consecutive leucines (Leu); and 1, 2, 3, or 4 repeats of peptide of SEQ ID NO: 1 linked thereto.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the peptide of SEQ ID NO: 1 is linked to the C-terminal of leucine (Leu).

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises 10 or 11 consecutive leucines (Leu); and 2, 3, or 4 repeats of peptide of SEQ ID NO: 1 linked thereto.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide has any one sequence selected from the group consisting of SEQ ID NOS: 2 to 13.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein the polypeptide has the sequence of SEQ ID NO: 7, 8, 11 or 12.

### Claim 6

A composition for intracellular transfection, comprising:
a polypeptide comprising 9, 10, or 11 consecutive leucines (Leu) and 1, 2, 3, or 4 repeats of peptide of SEQ ID NO: 1 linked thereto; and
a target substance.

### Claim 7 (depends on 6)

The composition for intracellular transfection of claim 6, wherein the target substance is a compound, a protein, a nucleic acid or a drug.

### Claim 8 (depends on 7)

The composition for intracellular transfection of claim 7, wherein the protein is at least one selected from the group consisting of an antibody, a receptor-bindable ligand peptide, a protein drug, a cytotoxic polypeptide, a cytotoxic protein, and a fluorescent protein.

### Claim 9 (depends on 7)

The composition for intracellular transfection of claim 7, wherein the nucleic acid is selected from the group consisting of DNA, recombinant DNA, plasmid DNA, antisense oligonucleotide, aptamer, RNA, siRNA, shRNA, and miRNA.

### Claim 10 (depends on 6)

The composition for intracellular transfection of claim 6, wherein the polypeptide is any one selected from the group consisting of SEQ ID NOS: 2 to 13.

### Claim 11 (depends on 6)

The composition for intracellular transfection of claim 6, wherein the polypeptide forms a membrane to provide an outer layer with an inner compartment, thereby loading the target substance.

### Claim 12 (depends on 6)

The composition for intracellular transfection of claim 6, wherein the cell is any one selected from the group consisting of a stem cell, a primary cell, an immune cell, a cancer cell, an epithelial cell, a skin cell, a gastrointestinal cell, a mucosal cell, and a lung cell.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 7)

The composition for intracellular transfection of claim 7, wherein the drug is any one selected from the group consisting of a compound drug, a bio drug, a nucleic acid drug, a peptide drug, a protein drug, a hormone, a contrast agent, and an antibody.

### Claim 23

A method for delivering a target substance into a cell, comprising:
contacting the cell with a composition for intracellular transfection, comprising a polypeptide comprising 9, 10, or 11 consecutive leucines (Leu) and 1, 2, 3, or 4 repeats of peptide of SEQ ID NO: 1 linked thereto; and a target substance.

### Claim 24 (depends on 23)

The method for delivering a target substance into a cell of claim 23, wherein the target substance is a compound, a protein, a nucleic acid, or a drug.

### Claim 25 (depends on 24)

The method for delivering a target substance into a cell of claim 24, wherein the protein is at least one selected from the group consisting of an antibody, a receptor-bindable ligand peptide, a protein drug, a cytotoxic polypeptide, a cytotoxic protein, and a fluorescent protein.

### Claim 26 (depends on 24)

The method for delivering a target substance into a cell of claim 24, wherein the nucleic acid is selected from the group consisting of DNA, recombinant DNA, plasmid DNA, antisense oligonucleotide, aptamer, RNA, siRNA, shRNA, and miRNA.

### Claim 27 (depends on 24)

The method for delivering a target substance into a cell of claim 24, wherein the drug is any one selected from the group consisting of a compound drug, a bio drug, a nucleic acid drug, a peptide drug, a protein drug, a hormone, a contrast agent, and an antibody.

### Claim 28 (depends on 23)

The method for delivering a target substance into a cell of claim 23, wherein the polypeptide is any one selected from the group consisting of SEQ ID NOS: 2 to 13.

### Claim 29 (depends on 23)

The method for delivering a target substance into a cell of claim 23, wherein the cell is any one selected from the group consisting of a stem cell (e.g., an embryonic stem cell, a pluripotent stem cell, an induced pluripotent stem cell, a neural stem cell, a mesenchymal stem cell, a hematopoietic stem cell, a peripheral blood stem cell), a primary cell (e.g., a myoblast, a fibroblast), an immune cell (e.g., a NK cell, a T cell, a dendritic cell, an antigen presenting cell), a cancer cell, an epithelial cell, a skin cell, a gastrointestinal cell, a mucosal cell, or a lung cell.
